Jerauld S. Skotnicki

Author

Also Known As

J Skotnicki, J. S. SKOTNICKI, J. S. Skotnicki, J. Skotnicki, J.S Skotnicki, J.S. Skotnicki, JERAULD S. SKOTNICKI, JERAULD SKOTNICKI, Jerauld S Skotnicki, Jerauld S. Skotnicki

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Pearl River Community College Princeton University Women's Health Research Institute Pfizer (United States)Amgen (United States)

About

Jerauld S. Skotnicki is an author at Pearl River Community College specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	24	1.5K
2	Biochemistry	14	15	488
3	Natural Sciences	13	14	498
4	Engineering	3	3	280
5	Public Health	1	1	103

Jerauld S. Skotnicki

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Ker Yu, Lourdes Toral‐Barza, Carolyn Discafani, Endocrine Related Cancer Breast OncologyCell CycleCancer BiologyTumor BiologySensitive Lines	2001	418
Reactions of sodium borohydride in acidic media. I. Reduction of indoles and alkylation of aromatic amines with carboxylic acids Gordon W. Gribble, Pierre D. Lord, Jerauld S. Skotnicki, Journal of the American Chemical Society Acidic MediaChemical EngineeringEngineeringChemical AnalysisAltmetric Attention Score	1974	240
Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities Benfang Helen Ruan, Kevin Pong, Flora Jow, Proceedings of the National Academy of Sciences Immunophilin LigandsCell DeathSynaptic SignalingNeuroinflammationMolecular Pharmacology	2007	111
Biosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismate Jennifer N. Andexer, Steven G. Kendrew, Mohammad Nur‐e‐Alam, Proceedings of the National Academy of Sciences	2011	107
Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis Yonghan Hu, Jason Xiang, Martin DiGrandi, Bioorganic & Medicinal Chemistry MedicineChronic Musculoskeletal ConditionOsteoarthritisPharmacologyMusculoskeletal Research	2005	107
Comparison of Human and Rat Uterine Leiomyomata: Identification of a Dysregulated Mammalian Target of Rapamycin Pathway Judy S. Crabtree, Scott A. Jelinsky, Heather A. Harris, Cancer Research Uterine LeiomyomataRapamycin Analogue Way-129327Uterine FibroidsHormonal ReceptorPathology	2009	103
Inhibition of Matrix Metalloproteinases: Structure Based Design Arie Zask, Jeremy I. Levin, Loran M. Killar, Current Pharmaceutical Design Medicinal ChemistryBiochemistryMedicineNatural SciencesMatrix Metalloproteinases	1996	75
Synthesis and Structure−Activity Relationship of N-Substituted 4-Arylsulfonylpiperidine-4-hydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of Osteoarthritis Venkatesan Aranapakam, Jamie M. Davis, G Grosu, Journal of Medicinal Chemistry Medicinal ChemistryPharmaceutical ChemistryPharmaceutical ScienceAnti-inflammatoryBiochemistry	2003	69
PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors Ker Yu, Judy Lucas, Tianmin Zhu, Cancer Biology & Therapy	2005	65
Synthesis and Structure−Activity Relationship of α-Sulfonylhydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of Osteoarthritis Venkatesan Aranapakam, G Grosu, Jamie M. Davis, Journal of Medicinal Chemistry Pharmaceutical ScienceChemical BiologyPharmaceutical ChemistryInflammationMedicinal Chemistry	2003	63

Page 1